Format

Send to

Choose Destination
See comment in PubMed Commons below
Bull NYU Hosp Jt Dis. 2011;69(3):233-7.

Promising new treatments for rheumatoid arthritis - the kinase inhibitors.

Author information

1
Division of Rheumatology and Medicine, NYU Hospital for Joint Diseases, New York, New York, USA. yazici@nyumc.org

Abstract

Three major advances over the last decade have impacted the way we treat rheumatoid arthritis; early and aggressive treatment, use of disease activity measures leading to treat to target, and availability of biologic agents. No oral biologic agents are available at this time but promising data is emerging for two drugs, tofacitinib and fostamatinib, inhibitors of JAK and Syk kinases, respectively. This paper will review some of the relevant published data for these agents and discuss where they may be placed in our treatment options for RA.

PMID:
22035435
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bulletin of the NYU Hospital for Joint Diseases
    Loading ...
    Support Center